Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 726

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 726
---
 owned by Cara stockholders(1)                    | ​ | ​ | ​ | ​ | 2,325,606 | ​ | ​ |
|:--|:---------------------------------------------------------------------------------------|:--|:--|:--|:--|----------:|:--|:--|
| ​ | Multiplied by the fair value per share of Cara common stock(2)                         | ​ | ​ | ​ | $ |      9.68 | ​ | ​ |
| ​ | Total                                                                                  | ​ | ​ | ​ | $ |    22,512 | ​ | ​ |
| ​ | Estimated fair value of assumed Cara stock-based awards based on pre-Merger service(3) | ​ | ​ | ​ | ​ |       255 | ​ | ​ |
| ​ | Total estimated purchase price                                                         | ​ | ​ | ​ | $ |    22,767 | ​ | ​ |

(1) The final purchase price was determined based on the number of shares of Cara common stock that Cara stockholders owned immediately prior to the closing of the Merger, after giving effect to the

423

TABLE OF CONTENTS

proposed Reverse Stock Split at an assumed ratio of 1-for-2. For purposes of this unaudited pro forma combined financial information, the estimated number of shares represents 2,285,276 shares of Cara common stock outstanding as of September 30, 2024, 738 RSUs that vested subsequent to September 30, 2024 and 39,592 unvested RSUs outstanding as of the date of this proxy statement/prospectus, which will become vested in full upon the Closing. (2) The estimated preliminary purchase price is based on the closing price on The Nasdaq Capital Market on January 31, 2025, and adjusted to give the effect to the proposed Reverse Stock Split at an assumed ratio of 1-for-2. (3) Reflects the estimated acquisition-date fair value of the assumed Cara equity awards attributable to pre-Merger service expected to be outstanding as of the Effective Time. This is included as an adjustment to the unaudited pro forma condensed combined balance sheet by crediting and debiting additional paid-in capital, resulting in no impact to the unaudited pro forma condensed combined financial information. The actual purchase price for the assets of Cara will vary based on, among other things, the net cash calculation prior to the Closing, the Exchange Ratio and the Cara share price at the Closing. As such, the estimated